<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01910363</url>
  </required_header>
  <id_info>
    <org_study_id>A1A2BONT</org_study_id>
    <secondary_id>TU001</secondary_id>
    <nct_id>NCT01910363</nct_id>
  </id_info>
  <brief_title>Study of a New Generation Botulinum Toxin A2NTX to Treat Spasticity After Stroke</brief_title>
  <acronym>A2NTX</acronym>
  <official_title>Comparison of Clinical Efficacy of Botulinum Neurotoxin Type A1 and A2 for Post-Stroke Lower Limb Spasticity: Phase 2/3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Tokushima</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Labour and Welfare, Japan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Tokushima</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To test the safety and efficacy of a new generation botulinum toxin preparation A2NTX for
      treating stroke patients with lower limb spasticity.

        -  we study the degree of spasticity in the ankle and knee joints, and walking speed in 30
           patients with stroke before and after injecting 300 units of BOTOX or A2NTX in a blinded
           manner as for the patient, the physician, and the examiner.

        -  we also assess the safety of A2NTX and compare it to that of BOTOX.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2013</start_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Modified Ashworth Scale of the ankle joint</measure>
    <time_frame>30-60 days after injection</time_frame>
    <description>Modified Ashworth Scale is measured at baseline, 30(27-33) days and 60 (56-63) days after injection. Area under curve of Modified Ashworth Scale changes at day 30 and day 60 after injection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Functional Independence Measure (FIM)</measure>
    <time_frame>30 days after injection</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Walking Speed for 3m</measure>
    <time_frame>30 days after injection</time_frame>
    <description>Time required for a patient to stand up from sitting position in a chair of 50cm height and walk for 3m.
If assistance is needed, the same method of assisting the patient is used throughout the study.</description>
  </other_outcome>
  <other_outcome>
    <measure>grasp power</measure>
    <time_frame>30 days after injection</time_frame>
    <description>Grasping power of both upper limbs will be measure with a standard grasp measure device in kg units. Because injection is made into lower limbs, any decrease of grasp power will be assessed as the measure of unwanted spread of the toxin action.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Lower Limb Spasticity After Stroke</condition>
  <arm_group>
    <arm_group_label>A2NTX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single intramuscular injection of 300 units of A2NTX, a purified low molecular weight (150 kDalton) botulinum toxin preparation of type A2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BOTOX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single intramuscular injection of 300 units of BOTOX®, a commercially available botulinum toxin preparation of type A1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A2NTX</intervention_name>
    <description>Intramuscular injection of the botulinum toxin preparation in 300 units (mouse LD50) into tibialis posterior and medial gastrocnemius muscles on the affected side.</description>
    <arm_group_label>A2NTX</arm_group_label>
    <other_name>A2NTX:low molecular weight (150kDalton) purified botulinum toxin type A2 preparation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BOTOX</intervention_name>
    <description>Intramuscular injection of the botulinum toxin preparation in 300 units (mouse LD50) into tibialis posterior and medial gastrocnemius muscles on the affected side.</description>
    <arm_group_label>BOTOX</arm_group_label>
    <other_name>BOTOX®:onabotulinumtoxinA (Allergan Co Ltd), commercially available botulinum toxin type A1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with lower limb spasticity after stroke

          -  duration more than 6 months

          -  Modified Ashworth Scale of ankle joint more than 2

        Exclusion Criteria:

          -  patients with previous botulinum toxin injections to lower limbs

          -  patients with serious hepatic, renal or cardiac dysfunction

          -  patients with respiratory failure

          -  patients who cannot understand the instructions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tokushima University Hospital</name>
      <address>
        <city>Tokushima</city>
        <zip>770-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2013</study_first_submitted>
  <study_first_submitted_qc>July 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2013</study_first_posted>
  <last_update_submitted>January 9, 2014</last_update_submitted>
  <last_update_submitted_qc>January 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Tokushima</investigator_affiliation>
    <investigator_full_name>Ryuji Kaji</investigator_full_name>
    <investigator_title>Professor and Chairman, Department of Neurology</investigator_title>
  </responsible_party>
  <keyword>poststroke spasticity</keyword>
  <keyword>lower limb</keyword>
  <keyword>botulinum toxin</keyword>
  <keyword>A2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Muscle Spasticity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>November 18, 2017</submitted>
    <submission_canceled>May 24, 2018</submission_canceled>
    <submitted>May 24, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

